Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NLP91
- Development stage
- Preclinical
- Lead developer
- NovaLead Pharma
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
NLP91 is a small molecule drug candidate developed by NovaLead Pharma for the treatment of psoriasis and other inflammatory skin diseases. It is based on an FDA-approved generic drug molecule that has demonstrated novel anti-inflammatory activity, discovered through in-silico screening and validated in vitro. The drug is being developed as a topical therapy targeting mild-to-moderate psoriasis, which represents the majority of psoriasis cases. As of March 2025, NLP91 remains in preclinical development with ongoing animal model studies to further validate its efficacy and safety.
Beyond the preview
Go deeper on NLP91.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NLP91.